S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

DexCom (DXCM) Stock Price, News & Analysis

$134.30
+0.44 (+0.33%)
(As of 04/18/2024 ET)
Today's Range
$133.58
$135.98
50-Day Range
$114.22
$140.45
52-Week Range
$74.75
$142.00
Volume
2.12 million shs
Average Volume
2.98 million shs
Market Capitalization
$51.78 billion
P/E Ratio
102.52
Dividend Yield
N/A
Price Target
$141.40

DexCom MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
5.3% Upside
$141.40 Price Target
Short Interest
Healthy
3.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.91mentions of DexCom in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$25.53 M Sold Last Quarter
Proj. Earnings Growth
26.70%
From $1.76 to $2.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

125th out of 919 stocks

Surgical & Medical Instruments Industry

20th out of 93 stocks

DXCM stock logo

About DexCom Stock (NASDAQ:DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Stock Price History

DXCM Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. NASDAQ: DXCM is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to monitor their blood glucose levels.
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People
DexCom (DXCM) Set to Announce Earnings on Thursday
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
RBC Capital Keeps Their Buy Rating on Dexcom (DXCM)
DexCom (DXCM) Stock Moves -1.16%: What You Should Know
UBS Group Boosts DexCom (NASDAQ:DXCM) Price Target to $163.00
The Analyst Verdict: DexCom In The Eyes Of 4 Experts
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
4/18/2024
Next Earnings (Confirmed)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
Employees
9,600
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$141.40
High Stock Price Target
$165.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+4.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Net Income
$541.50 million
Pretax Margin
19.61%

Debt

Sales & Book Value

Annual Sales
$3.62 billion
Cash Flow
$2.05 per share
Book Value
$5.35 per share

Miscellaneous

Free Float
383,934,000
Market Cap
$52.12 billion
Optionable
Optionable
Beta
1.20

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in DexCom, Inc.:

  • DexCom's recent growth initiatives have led to a significant increase in its total primary care prescriber base and the number of new patients starting in primary care, indicating a positive trajectory for the company.
  • The Centers for Medicare and Medicaid Services' approval of expanded coverage for CGM products to a wider group of type 2 diabetics has opened up a larger market of potential users for DexCom, including those who don't require insulin treatment and those with low blood sugar.
  • The company's innovative Dexcom G7 continuous glucose monitoring system, highlighted in a Super Bowl ad, offers a cutting-edge solution for diabetes management by eliminating the need for finger blood draws and providing real-time glucose readings directly to smartphones or smartwatches.
  • DexCom's aim to expand into additional patient markets such as Type 2 Non-Insulin, Pre-Diabetes, Gestational Diabetes, Patient Monitoring, and Health & Wellness indicates a strategic approach towards diversification and growth.
  • With DexCom shares currently in the buy range after clearing a specific buy point, there may be a favorable entry point for investors looking to capitalize on the company's potential growth.

Cons

Investors should be bearish about investing in DexCom, Inc. for these reasons:

  • Market volatility and potential pullbacks in the broader market could impact DexCom's stock price, leading to short-term fluctuations that may require cautious consideration by investors.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DXCM Stock Analysis - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings
or view top-rated stocks.

What is DexCom's stock price target for 2024?

14 brokerages have issued 1 year target prices for DexCom's shares. Their DXCM share price targets range from $100.00 to $165.00. On average, they predict the company's share price to reach $141.40 in the next year. This suggests a possible upside of 5.3% from the stock's current price.
View analysts price targets for DXCM
or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2024?

DexCom's stock was trading at $124.09 at the start of the year. Since then, DXCM stock has increased by 8.2% and is now trading at $134.30.
View the best growth stocks for 2024 here
.

Are investors shorting DexCom?

DexCom saw a decline in short interest in March. As of March 31st, there was short interest totaling 14,570,000 shares, a decline of 8.2% from the March 15th total of 15,870,000 shares. Based on an average daily volume of 3,090,000 shares, the days-to-cover ratio is currently 4.7 days.
View DexCom's Short Interest
.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our DXCM earnings forecast
.

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) released its quarterly earnings data on Thursday, February, 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.07. The medical device company had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.95% and a trailing twelve-month return on equity of 28.31%. The firm's revenue was up 26.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.34 earnings per share.
Read the conference call transcript
.

When did DexCom's stock split?

DexCom's stock split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were issued to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vaughan Nelson Investment Management L.P. (0.37%), Allspring Global Investments Holdings LLC (0.33%), Congress Asset Management Co. MA (0.29%), Los Angeles Capital Management LLC (0.09%), Congress Wealth Management LLC DE (0.04%) and AMF Tjanstepension AB (0.02%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends
.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does DexCom have any subsidiaries?
The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More
This page (NASDAQ:DXCM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners